$ATNMAug 14, 2026, 5:04 PM ETAI processed
Actinium adds Actimab‐A patents, expands manufacturing and gets NYSE compliance extension
AI Summary
Actinium (ATNM) announced multiple new patents expanding Actimab‐A IP—including US patents for targeting tumor‐resident MDSCs in solid tumors and issued/pending patents for AML and combination uses—and said it amended its IND to add an additional manufacturer to expand capacity ahead of clinical milestones expected Q4 2026 into 2027. NYSE Regulation accepted the company's compliance plan and granted the maximum cure period through November 27, 2027, keeping ATNM listed while the company works to meet listing standards.
Positives
- Multiple new US patents issued that extend Actimab‑A IP into solid tumors via MDSC targeting and add issued patents covering AML and combination therapies
- IND amended to add an additional manufacturer to increase supply capacity for NCI CRADA studies and company‑sponsored trials
- NYSE accepted the company’s compliance plan and granted a plan period through Nov 27, 2027, allowing continued listing on NYSE American
Negatives
- Company is currently not in compliance with NYSE American continued listing standards (Sections 1003(a)(ii) and 1003(a)(iii))
- Several patent applications remain pending internationally, leaving some uncertainty in global patent coverage
- Clinical milestones and data readouts are prospective (expected from H2 2026 into 2027) and not yet realized